<DOC>
	<DOCNO>NCT01491607</DOCNO>
	<brief_summary>The purpose Phase 3 clinical trial evaluate immunogenicity safety BioThrax anthrax vaccine healthy adult follow 3 dos BioThrax . Results study use support post-exposure prophylaxis ( PEP ) indication BioThrax . This study conduct United States ( U.S. ) , 200 healthy male female volunteer subject age 18 65 year . The duration study participation individual subject approximately 128 day ( 4.25 month ) , include screen period approximately 28 day follow 100 day study .</brief_summary>
	<brief_title>Immunogenicity Safety Study Three-Dose BioThrax® Regimen Post-Exposure Prophylaxis Healthy Adults</brief_title>
	<detailed_description>BioThrax® ( also call Anthrax Vaccine Adsorbed AVA ) FDA-licensed vaccine prevention anthrax infection . This study evaluate immunogenicity vaccine use post-exposure vaccination schedule . Correlations draw immunogenicity survival data animal model demonstrate BioThrax® elicit protective immune response PEP .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<criteria>Be 18 65 year age , inclusive , time enrollment . Be good health determine investigator medical history physical examination . If premenopausal female , must use acceptable method birth control . Have hematology chemistry parameter ( measure Screening ) within laboratory 's normal range . Be willing able return visit blood collection duration study . Have read , understood sign informed consent form . Prior immunization anthrax vaccine know exposure anthrax organism . Intend enlist military study . Have know allergy aluminum hydroxide , formaldehyde , benzethonium chloride , latex . Plan receive experimental product time study . Have receive live vaccine 30 day study entry . Plan receive live vaccine time study . Have ongoing drug abuse/dependence ( include alcohol ) issue and/or test positive urine drug screen amphetamine , barbiturate , cocaine opiate ; Have receive immunosuppressive therapy ( include systemic steroid ) within 3 month prior study entry . Have condition know produce associate immunosuppression . Have receive cytotoxic therapy previous 5 year . A medical condition , opinion Principal Investigator ( PI ) , could adversely impact subject 's participation , safety , conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>post-exposure prophylaxis</keyword>
	<keyword>toxin neutralization assay</keyword>
</DOC>